First AD

Second AD

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2+ breast cancer treatment and management strategies.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2+ Breast Cancer

SEA-22-OSD1249 - /clinical/her2-positive-neoadjuvant-care

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Management of Advanced HER2+ Breast Cancer

OncLive News Network®

Memorial Sloan Kettering Cancer Center 

Cancer Centers

Partner

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them. 


Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

Optimal Management Strategies in Advanced HER2+ Breast Cancer

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer